A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Overview

About this study

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria (sporadic CAA patients):
-Is 50 years or older -Has probable CAA per the Boston Criteria Version 2.0

Inclusion Criteria (Dutch-type CAA patients):
-Is 30 years or older
-Has known E693Q amyloid precursor protein (APP) gene mutation for Dutch-type CAA


Exclusion Criteria:
-Moderate or severe stage Alzheimer's disease (AD) or significant cognitive impairment (CI)
-Has a history of previous clinical intracerebral hemorrhage (ICH) with onset less than 90 days prior to anticipated randomization in the study
-Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3×upper limit of normal (ULN) at Screening
-Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m^2 at Screening
-Has recently received an investigational agent
-Has had treatment with amyloid-targeting antibody Note: other protocol defined inclusion / exclusion criteria apply

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/7/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Eugene Scharf, M.D.

Contact us for the latest status

Contact information:

Brenda Nelson

(507) 284-1588

Nelson.Brenda6@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20575115

Mayo Clinic Footer